Allogene Therapeutics, Inc. (ALLO) Market Cap & Valuation Ratios
Allogene Therapeutics, Inc. (ALLO) has a market cap of $431.9M and a price-to-sales ratio of 93.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALLOAllogene Therapeutics, Inc.Follow ALLO — free
—
Price chart with a free account
- Market cap
- 431.9M
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| ALLO | 0.4 | — | 21.4 | — | — | — | — | -52% |
| ARVN | 0.5 | 30.4 | — | — | — | -15% | -6% | -4% |
| MNPR | 0.5 | — | — | — | -2.6% | — | — | -49% |
| NGNE | 0.5 | — | — | — | — | — | — | -76% |
| PHAT | 0.5 | — | 1.9 | — | -7.9% | +110% | -17% | — |
| RGNX | 0.4 | — | 1.9 | — | — | +12% | -94% | -194% |
| PRTA | 0.4 | — | 2.4 | — | -14.4% | +427% | -102% | — |
| ALT | 0.4 | — | — | — | — | +105% | — | -22% |
| AUTL | 0.4 | — | 1.8 | — | — | +292% | -211% | — |
| SPRY | 0.4 | — | 3.0 | — | — | +4% | -185% | -214% |
| TECX | 0.4 | — | — | — | — | — | — | — |
| Median of these 10 | 30.4 | 1.9 | — | -7.9% | +105% | -98% | -62% |
; EV/Sales 21.4 vs. 1.9.
Growth vs. price
each dot a company · hover or tap for valuesAllogene Therapeutics, Inc. — questions
- What is Allogene Therapeutics, Inc.'s market cap?
- $431.9M.
- What is Allogene Therapeutics, Inc.'s price-to-sales ratio?
- 93.1.
Every figure on this page comes from Allogene Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.